Pathologic complete response to neoadjuvant imatinib of a gastric stromal tumor with concomitant mutations in <scp><i>KIT</i></scp>: A case report and literature review-Reference-Cited by-同舟云学术

Pathologic complete response to neoadjuvant imatinib of a gastric stromal tumor with concomitant mutations in KIT: A case report and literature review

Published:2023-06 Issue:6 Volume:11 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clinical Case Reports

Author:

Rekaya Mariem Ben¹²,Ksontini Feryel³,Kacem Linda Bel Haj¹²,Sassi Farah²^ORCID,Harigua‐Souiai Emna⁴,Boujneh Ryma³,H'mayada Ahmed¹,Zaimi Yosra⁵,Ayadi Mouna³,Trabelsi Mediha⁶,Mrad Ridha⁶,Rammeh Soumaya¹²

Affiliation:

1. Theranostic Biomarkers, UR17ES15, Faculty of Medicine of Tunis Université Tunis El Manar Tunis Tunisia

2. Pathology Department Charles Nicolle Hospital Tunis Tunisia

3. Medical Oncology Department Salah Azaiez Institute Tunis Tunisia

4. Laboratory of Molecular Epidemiology and Experimental Pathology – LR16IPT04 Institut Pasteur de Tunis, Université de Tunis El Manar Tunis Tunisia

5. Gastroenterology Department Charles Nicolle Hospital Tunis Tunisia

6. Department of Hereditary and Congenital Disorders Charles Nicolle Hospital Tunis Tunisia

Abstract

Key clinical messageWe report the first case of pathologic complete response (pCR) to neoadjuvant imatinib in a gastric stromal tumor harboring KIT mutations in both exons 11 and 9. The significance of this co‐occurrence is unknown and might increase the responsiveness of gastrointestinal stromal tumors (GISTs) to imatinib.AbstractpCR of GIST to neoadjuvant imatinib is rare. We report a case of pCR to neoadjuvant imatinib in a gastric stromal tumor that harbored co‐occurrence of multiple KIT mutations in exons 11 and 9. This co‐occurrence in exons 9 and 11 is the first to be reported in the English literature.

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.7463

Reference39 articles.

1. Clinical significance of oncogenicKITandPDGFRAmutations in gastrointestinal stromal tumours

2. Response assessment in gastrointestinal stromal tumor

3. Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors

4. Clinical significance of pathological complete response in patients with metastatic gastrointestinal stromal tumors after imatinib mesylate treatment—lessons learned;Cheng C;Anticancer Res,2014

5. Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon